Cargando…
Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect
BACKGROUND: Monoclonal antibodies (mAbs) have been used for cancer therapy. They are large and have some disadvantages limiting their use. Smaller antibody fragments are needed as their alternatives. A fully human single-domain antibody (sdAb) has a small size of only 15 kDa and consists of only the...
Autores principales: | Chen, Tao, Liu, Xue, Hong, Haifeng, Wei, Henry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541222/ https://www.ncbi.nlm.nih.gov/pubmed/33023595 http://dx.doi.org/10.1186/s12967-020-02538-y |
Ejemplares similares
-
Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
por: Makabe, Koki, et al.
Publicado: (2021) -
Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies
por: D’Souza, Jimson W., et al.
Publicado: (2014) -
Isolation and Epitope Mapping of Staphylococcal Enterotoxin B Single-Domain Antibodies
por: Turner, Kendrick B., et al.
Publicado: (2014) -
Linking Single Domain Antibodies that Recognize Different Epitopes on the Same Target
por: Glaven, Richard H., et al.
Publicado: (2012) -
Isolation and characterization of camelid single-domain antibodies against HER2
por: Hussack, Greg, et al.
Publicado: (2018)